PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Horizon Therapeutics Public Limited Company (HZNP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINIE00BQPVQZ61
CUSIP00BQPVQZ6
SectorHealthcare
IndustryDrug Manufacturers—General

Highlights

Market Cap$26.63B
EPS$1.88
PE Ratio61.86
PEG Ratio1.00
Revenue (TTM)$3.64B
Gross Profit (TTM)$2.80B
EBITDA (TTM)$669.21M
Year Range$90.56 - $116.38
Target Price$116.50
Short %3.12%
Short Ratio2.04

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Horizon Therapeutics Public Limited Company

Popular comparisons: HZNP vs. XLV, HZNP vs. SMCI, HZNP vs. QQQ, HZNP vs. AMGN

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Horizon Therapeutics Public Limited Company, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


HZNP (Horizon Therapeutics Public Limited Company)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A5.90%
1 monthN/A-1.28%
6 monthsN/A15.51%
1 yearN/A21.68%
5 years (annualized)N/A11.74%
10 years (annualized)N/A10.50%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20232.62%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Horizon Therapeutics Public Limited Company (HZNP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


HZNP
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.89, compared to the broader market-2.00-1.000.001.002.003.001.89
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.74, compared to the broader market-4.00-2.000.002.004.006.002.74
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.001.002.003.004.005.001.43
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.62, compared to the broader market-10.000.0010.0020.0030.007.62

Sharpe Ratio


Rolling 12-month Sharpe Ratio
HZNP (Horizon Therapeutics Public Limited Company)
Benchmark (^GSPC)

Dividends

Dividend History


Horizon Therapeutics Public Limited Company doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


HZNP (Horizon Therapeutics Public Limited Company)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Horizon Therapeutics Public Limited Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Horizon Therapeutics Public Limited Company was 78.25%, occurring on Mar 4, 2013. Recovery took 229 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-78.25%Jul 29, 2011400Mar 4, 2013229Jan 29, 2014629
-74.92%Jul 22, 2015455May 10, 2017678Jan 22, 20201133
-52.36%Mar 24, 201489Jul 29, 2014142Feb 20, 2015231
-50.86%Nov 1, 2021208Aug 30, 2022
-35.5%Jan 23, 202042Mar 23, 202031May 6, 202073

Volatility

Volatility Chart

The current Horizon Therapeutics Public Limited Company volatility is 0.90%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


HZNP (Horizon Therapeutics Public Limited Company)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Horizon Therapeutics Public Limited Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items